HC Wainwright Has Pessimistic Outlook of CTMX Q1 Earnings

CytomX Therapeutics, Inc. (NASDAQ:CTMX) – Stock analysts at HC Wainwright decreased their Q1 2026 EPS estimates for CytomX Therapeutics in a report released on Monday, March 16th. HC Wainwright analyst M. Kapoor now expects that the biotechnology company will post earnings per share of ($0.14) for the quarter, down from their previous forecast of ($0.08). HC Wainwright currently has a “Buy” rating and a $17.00 target price on the stock. The consensus estimate for CytomX Therapeutics’ current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for CytomX Therapeutics’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.56) EPS and FY2027 earnings at ($0.65) EPS.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings results on Monday, March 16th. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The business had revenue of $0.66 million for the quarter, compared to analysts’ expectations of $7.33 million. CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 19.77%.

Other equities analysts have also issued reports about the company. Oppenheimer reaffirmed an “outperform” rating and issued a $12.00 price target on shares of CytomX Therapeutics in a report on Monday. JPMorgan Chase & Co. upgraded CytomX Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $7.00 to $12.00 in a research note on Monday. Guggenheim increased their price objective on CytomX Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday. Piper Sandler raised their target price on CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Finally, Jefferies Financial Group lifted their target price on CytomX Therapeutics from $8.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday. Nine research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $12.56.

CytomX Therapeutics Trading Down 19.3%

CytomX Therapeutics stock opened at $4.40 on Wednesday. The firm has a 50 day simple moving average of $5.27 and a 200 day simple moving average of $4.10. CytomX Therapeutics has a 1-year low of $0.40 and a 1-year high of $8.21. The firm has a market capitalization of $748.84 million, a price-to-earnings ratio of -110.00 and a beta of 2.44.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Orbimed Advisors LLC bought a new stake in CytomX Therapeutics during the second quarter valued at $19,208,000. Commodore Capital LP bought a new position in CytomX Therapeutics in the 2nd quarter worth about $17,462,000. Perceptive Advisors LLC purchased a new stake in shares of CytomX Therapeutics in the 2nd quarter valued at about $15,876,000. Franklin Resources Inc. purchased a new stake in shares of CytomX Therapeutics in the 2nd quarter valued at about $13,096,000. Finally, Vivo Capital LLC bought a new stake in shares of CytomX Therapeutics during the 2nd quarter valued at about $13,096,000. Institutional investors own 67.77% of the company’s stock.

Trending Headlines about CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Multiple analysts raised price targets or upgraded the stock — Guggenheim raised its target to $15 and put a Buy on CTMX, Wedbush raised its target to $11 with an Outperform, and JPMorgan issued an upgrade — these notes signal continued institutional interest and provide upside conviction for the shares. Benzinga JPMorgan Upgrade
• Positive Sentiment: Clinical catalyst: strong Phase I Varseta‑M data in metastatic colorectal cancer previously triggered a rally and underpins investor optimism about the pipeline’s upside. Zacks
• Neutral Sentiment: Company posted its Q4 results presentation (useful for diligence), providing the latest formal disclosures on operations and pipeline progress. Investors should review the deck for cash runway details and program timelines. Q4 Presentation
• Negative Sentiment: Dilutive equity financing: CytomX priced a $250M offering at $5.30/share (≈46M shares plus pre‑funded warrants). The sale increases share count materially and is the primary near‑term headwind pressuring the stock. Offering Filing
• Negative Sentiment: HC Wainwright lowered near‑term EPS forecasts substantially (Q1–Q4 2026 and FY2026 cuts) even while maintaining a Buy and a $17 target; the reduced estimates highlight expected near‑term cash burn and push downside to short‑term earnings expectations. Analyst Note
• Negative Sentiment: Recent quarter missed consensus on EPS and revenue (reported March 16), underscoring why the company sought additional capital and why near‑term profitability looks distant. Earnings Coverage

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.